Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial

The Lancet Neurology

Fecha de publicación: Enero de 2022

Autores: Prof Alberto C S Costa, MD , Ana C Brandão, MD, Richard Boada, PhD, Veridiana L Barrionuevo, BS, Prof Hudson G Taylor, PhD, Elizabeth Roth, PhD, Melissa R Stasko, MA, Mark W Johnson, PhD, Fernanda F Assir, MS, Maria P Roberto, MS, Patrícia Salmona, MD, Guilherme Abreu-Silveira, MD, Ilya Bederman, PhD, Erin Prendergast, BS, Anke Hüls, PhD, Sarina Abrishamcar, BS, Zan Mustacchi, MD, Thomas Scheidemantel, MD, Prof Nancy J Roizen, MD, Prof Stephen Ruedrich, MD

DOI: https://doi.org/10.1016/S1474-4422(21)00369-0

Background: Down syndrome is a chromosomal disorder with considerable neurodevelopmental impact and neurodegenerative morbidity. In a pilot trial in young adults with Down syndrome, memantine (a drug approved for Alzheimer’s disease) showed a significant effect on a secondary measure of episodic memory. We aimed to test whether memantine would improve episodic memory in adolescents and young adults with Down syndrome.